US2014275553A1PendingUtilityA1

Substituted benzoazole pde4 inhibitors for treating pulmonary and cardiovascular disorders

Assignee: DECODE GENETICS EHFPriority: Nov 21, 2007Filed: May 28, 2014Published: Sep 18, 2014

Est. expiryNov 21, 2027(~1.4 yrs left)· nominal 20-yr term from priority

Inventors:Jasbir Singh Mark E. Gurney Alex Burgin Alexander Kiselyov Munagala Rao

A61P 9/06A61P 9/00A61P 9/10A61P 35/00A61P 43/00A61P 35/04A61P 29/00A61K 31/423A61P 11/06A61K 31/4439C07D 263/56A61K 31/519A61P 1/00C07D 498/04C07D 513/04C07D 417/06A61P 13/10A61P 13/02C07D 277/64C07D 417/04C07D 263/58A61P 19/10A61K 31/496A61K 31/454A61P 19/08C07D 417/14C07D 277/82A61K 31/428A61P 19/00A61P 11/00

PatentIndex Score

Cited by

References

Claims

Abstract

The invention relates to substituted benzothiazoles, benzoxazoles—and their counterparts having pyridine and pyrimidine rings replacing the benzene ring—that are PDE4 inhibitors useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions, to pharmaceutical compositions comprising these compounds, and to methods for the treatment of stroke, myocardial infarct, and cardiovascular inflammatory conditions in a mammal. The compounds have general formula I: in which A and B are carbocycles or heterocycles. A particular embodiment is

Claims

exact text as granted — not AI-modified

We claim: 
     
         1 - 30 . (canceled) 
     
     
         31 . The compound 2-amino-4-bromo-benzothiazole-6-carboxylic acid:

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.